Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Lyra Therapeutics reports Q3 EPS (49c), consensus (41c) » 16:09
11/10/20
11/10
16:09
11/10/20
16:09
LYRA

Lyra Therapeutics

$10.85 /

-0.18 (-1.63%)

"Having completed…

"Having completed our IPO in the second quarter, we were fully focused in the third quarter on executing our development plans for LYR-210 and LYR-220. I'm pleased to report that we are on track to deliver topline Phase 2 results from our LANTERN study in December, which we believe will be an important milestone for the company and shareholders alike," said Maria Palasis, Ph.D., President and Chief Executive Officer of Lyra Therapeutics. "We have also continued to build awareness about LYR-210 throughout the scientific and medical communities, with ongoing outreach and three presentations at the ARS Annual Meeting. In addition, I am delighted to welcome Dr. Nancy Snyderman to our board. Nancy has a deep understanding of the value of medical innovation as well as the barriers that must be overcome in order to bring new therapies to ENT physicians and patients and will bring a valuable perspective to Lyra."

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$10.85 /

-0.18 (-1.63%)

LYRA Lyra Therapeutics
$10.85 /

-0.18 (-1.63%)

05/26/20 BTIG
Lyra Therapeutics initiated with a Buy at BTIG
05/26/20 Jefferies
Jefferies starts Lyra Therapeutics at Buy with $24 price target
05/26/20 BofA
BofA starts Lyra Therapeutics at Buy with $21 price target
05/26/20 BofA
Lyra Therapeutics initiated with a Buy at BofA
LYRA Lyra Therapeutics
$10.85 /

-0.18 (-1.63%)

  • 01
    May
Over a month ago
Conference/Events
Jefferies healthcare analyst to hold analyst/industry conference call » 12:25
10/22/20
10/22
12:25
10/22/20
12:25
LYRA

Lyra Therapeutics

$11.90 /

-0.22 (-1.82%)

Healthcare Analyst…

Healthcare Analyst Howerton discusses Chronic Rhinosinusitis (CRS) and Lyra Therapeutics on an Analyst/Industry conference call to be held on October 22 at 1 pm.

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$11.90 /

-0.22 (-1.82%)

LYRA Lyra Therapeutics
$11.90 /

-0.22 (-1.82%)

05/26/20 BTIG
Lyra Therapeutics initiated with a Buy at BTIG
05/26/20 Jefferies
Jefferies starts Lyra Therapeutics at Buy with $24 price target
05/26/20 BofA
BofA starts Lyra Therapeutics at Buy with $21 price target
05/26/20 BofA
Lyra Therapeutics initiated with a Buy at BofA
LYRA Lyra Therapeutics
$11.90 /

-0.22 (-1.82%)

  • 01
    May
Conference/Events
Jefferies healthcare analyst to hold analyst/industry conference call » 09:25
10/22/20
10/22
09:25
10/22/20
09:25
LYRA

Lyra Therapeutics

$12.16 /

-0.4 (-3.18%)

Healthcare Analyst…

Healthcare Analyst Howerton discusses Chronic Rhinosinusitis (CRS) and Lyra Therapeutics on an Analyst/Industry conference call to be held on October 22 at 1 pm.

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$12.16 /

-0.4 (-3.18%)

LYRA Lyra Therapeutics
$12.16 /

-0.4 (-3.18%)

05/26/20 BTIG
Lyra Therapeutics initiated with a Buy at BTIG
05/26/20 Jefferies
Jefferies starts Lyra Therapeutics at Buy with $24 price target
05/26/20 BofA
BofA starts Lyra Therapeutics at Buy with $21 price target
05/26/20 BofA
Lyra Therapeutics initiated with a Buy at BofA
LYRA Lyra Therapeutics
$12.16 /

-0.4 (-3.18%)

  • 01
    May
Conference/Events
Lyra Therapeutics participates in a conference call with BTIG » 10:25
10/20/20
10/20
10:25
10/20/20
10:25
LYRA

Lyra Therapeutics

$12.65 /

-0.06 (-0.47%)

BTIG Healthcare Analyst…

BTIG Healthcare Analyst Hazlett holds a conference call with management to discuss elements of the Phase 2 Trial of Lyra's lead product, LYR-210 for Chronic Rhinosinutis (CRS), as well as the broader potential of Lyra's XTreo platform on October 20 at 11 am hosted by BTIG.

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$12.65 /

-0.06 (-0.47%)

LYRA Lyra Therapeutics
$12.65 /

-0.06 (-0.47%)

05/26/20 BTIG
Lyra Therapeutics initiated with a Buy at BTIG
05/26/20 Jefferies
Jefferies starts Lyra Therapeutics at Buy with $24 price target
05/26/20 BofA
BofA starts Lyra Therapeutics at Buy with $21 price target
05/26/20 BofA
Lyra Therapeutics initiated with a Buy at BofA
LYRA Lyra Therapeutics
$12.65 /

-0.06 (-0.47%)

  • 01
    May
Conference/Events
Lyra Therapeutics participates in a conference call with BTIG » 08:41
10/20/20
10/20
08:41
10/20/20
08:41
LYRA

Lyra Therapeutics

$12.65 /

-0.5 (-3.80%)

BTIG Healthcare Analyst…

BTIG Healthcare Analyst Hazlett holds a conference call with management to discuss elements of the Phase 2 Trial of Lyra's lead product, LYR-210 for Chronic Rhinosinutis (CRS), as well as the broader potential of Lyra's XTreo platform on October 20 at 11 am hosted by BTIG.

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$12.65 /

-0.5 (-3.80%)

LYRA Lyra Therapeutics
$12.65 /

-0.5 (-3.80%)

05/26/20 BTIG
Lyra Therapeutics initiated with a Buy at BTIG
05/26/20 Jefferies
Jefferies starts Lyra Therapeutics at Buy with $24 price target
05/26/20 BofA
BofA starts Lyra Therapeutics at Buy with $21 price target
05/26/20 BofA
Lyra Therapeutics initiated with a Buy at BofA
LYRA Lyra Therapeutics
$12.65 /

-0.5 (-3.80%)

  • 01
    May
Conference/Events
Lyra Therapeutics participates in a conference call hosted by BTIG » 11:08
10/19/20
10/19
11:08
10/19/20
11:08
LYRA

Lyra Therapeutics

$13.02 /

-0.13 (-0.99%)

Conference call with…

Conference call with management will be held on October 20 at 11 am hosted by BTIG.

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$13.02 /

-0.13 (-0.99%)

LYRA Lyra Therapeutics
$13.02 /

-0.13 (-0.99%)

05/26/20 BTIG
Lyra Therapeutics initiated with a Buy at BTIG
05/26/20 Jefferies
Jefferies starts Lyra Therapeutics at Buy with $24 price target
05/26/20 BofA
BofA starts Lyra Therapeutics at Buy with $21 price target
05/26/20 BofA
Lyra Therapeutics initiated with a Buy at BofA
LYRA Lyra Therapeutics
$13.02 /

-0.13 (-0.99%)

  • 01
    May
Hot Stocks
Lyra Therapeutics presents clinical data of LYR-210 in chronic rhinosinusitis » 18:05
09/10/20
09/10
18:05
09/10/20
18:05
LYRA

Lyra Therapeutics

$11.90 /

-0.45 (-3.64%)

Lyra Therapeutics…

Lyra Therapeutics presented data showing that LYR-210 demonstrated a "significant reduction" of sinonasal Type 2 inflammation in surgically naive patients with chronic rhinosinusitis. The reduction of Type 2 inflammation suggests a correlation with rhinologic symptom improvement in CRS and could be a potential measure of LYR-210's local anti-inflammatory effects at the site of inflammation in the sinonasal passages. The results showing LYR-210's influence on local Type 2 inflammatory response in CRS patients are secondary findings from the company's Phase 1 clinical study of LYR-210. The clinical finding of LYR-210's effect on Type 2 inflammation is presented as one of three poster presentations made by Lyra and its research collaborators at the 66th Annual Meeting of the American Rhinologic Society. LYR-210 significantly reduced sinonasal T2 inflammation markers IL-13, CCL26 and periostin in surgically naive CRS patients with and without polyps. Other T2 markers, IL-5 and CCL18, showed a trend toward reduction with LYR-210. Patients treated with a single administration of LYR-210 reported rapid, durable and clinically relevant improvement in CRS symptoms over the 24-week study.

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$11.90 /

-0.45 (-3.64%)

LYRA Lyra Therapeutics
$11.90 /

-0.45 (-3.64%)

05/26/20 BTIG
Lyra Therapeutics initiated with a Buy at BTIG
05/26/20 Jefferies
Jefferies starts Lyra Therapeutics at Buy with $24 price target
05/26/20 BofA
BofA starts Lyra Therapeutics at Buy with $21 price target
05/26/20 BofA
Lyra Therapeutics initiated with a Buy at BofA
LYRA Lyra Therapeutics
$11.90 /

-0.45 (-3.64%)

  • 01
    May
Over a quarter ago
Earnings
Lyra Therapeutics reports Q2 EPS (56c), consensus (38c) » 17:08
08/05/20
08/05
17:08
08/05/20
17:08
LYRA

Lyra Therapeutics

$14.00 /

+0.15 (+1.08%)

Cash and cash equivalents…

Cash and cash equivalents as of June 30, 2020 were $86.6 million, compared with $35.2 million as of March 31, 2020. The increase is attributable to proceeds received from Lyra's IPO, which occurred during the second quarter. "Lyra's second quarter IPO has placed the company in a position of strength. We expect to report topline Phase 2 results from our study of LYR-210, our lead product candidate, in chronic rhinosinusitis, in the fourth quarter of 2020," said Maria Palasis, Ph.D., President and Chief Executive Officer of Lyra Therapeutics. "We have also recently strengthened our management team with some key hires, which underscore our ongoing efforts to create further shareholder value by delivering on our existing drug candidates and expanding our development pipeline."

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$14.00 /

+0.15 (+1.08%)

LYRA Lyra Therapeutics
$14.00 /

+0.15 (+1.08%)

05/26/20 BTIG
Lyra Therapeutics initiated with a Buy at BTIG
05/26/20 Jefferies
Jefferies starts Lyra Therapeutics at Buy with $24 price target
05/26/20 BofA
BofA starts Lyra Therapeutics at Buy with $21 price target
05/26/20 BofA
Lyra Therapeutics initiated with a Buy at BofA
  • 01
    May
Hot Stocks
Lyra Therapeutics appoints Pamela Nelson as SVP, regulatory affairs » 08:54
08/04/20
08/04
08:54
08/04/20
08:54
LYRA

Lyra Therapeutics

$13.84 /

+0.61 (+4.61%)

Lyra Therapeutic…

Lyra Therapeutic announced the appointment of Pamela Nelson to the position of Senior Vice President of Regulatory Affairs. Before joining Lyra, Pamela served as Vice President, Regulatory Affairs at Avedro.

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$13.84 /

+0.61 (+4.61%)

LYRA Lyra Therapeutics
$13.84 /

+0.61 (+4.61%)

05/26/20 BTIG
Lyra Therapeutics initiated with a Buy at BTIG
05/26/20 Jefferies
Jefferies starts Lyra Therapeutics at Buy with $24 price target
05/26/20 BofA
BofA starts Lyra Therapeutics at Buy with $21 price target
05/26/20 BofA
Lyra Therapeutics initiated with a Buy at BofA
  • 01
    May
Hot Stocks
Lyra Therapeutics to join Russell 2000 Index, Russell 3000 Index » 08:26
06/25/20
06/25
08:26
06/25/20
08:26
LYRA

Lyra Therapeutics

$12.43 /

+1.21 (+10.78%)

Lyra Therapeutics…

Lyra Therapeutics announced that the company is set to join the small cap Russell 2000 Index and the broad-market Russell 3000 Index at the conclusion of this year's reconstitution of the Russell stock indexes, effective after the U.S. stock market opens on Monday, June 29, 2020, according to a preliminary list of additions posted June 5, 2020.

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$12.43 /

+1.21 (+10.78%)

05/26/20 BTIG
Lyra Therapeutics initiated with a Buy at BTIG
05/26/20 Jefferies
Jefferies starts Lyra Therapeutics at Buy with $24 price target
05/26/20 BofA
BofA starts Lyra Therapeutics at Buy with $21 price target
05/26/20 BofA
Lyra Therapeutics initiated with a Buy at BofA
LYRA Lyra Therapeutics
$12.43 /

+1.21 (+10.78%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.